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Cisplatin is widely used for treating various solid tumors. However, this drug produces dose-limiting ototoxicity and
nephrotoxicity, which signiﬁcantly reduce the quality of life of cancer patients. While nephrotoxicity could be alleviated by
diuresis, there is currently no approved treatment for hearing loss. Previous studies show that the ROS and inﬂammation are
major contributors to cisplatin-induced hearing loss. In this study, we show that ROS trigger the inﬂammatory process in the
cochlea by activating signal transducer and activator of transcription-1 (STAT1). Activation of STAT1 activation was dependent
on ROS generation through NOX3 NADPH oxidase, knockdown of which by siRNA reduced STAT1 activation. Moreover, STAT1
siRNA protected against activation of p53, reduced apoptosis, reduced damage to OHCs and preserved hearing in rats. STAT1
siRNA attenuated the increase in inﬂammatory mediators, such as TNF-a, inhibition of which protected cells from cisplatin-
mediated apoptosis. Finally, we showed that trans-tympanic administration of etanercept, a TNF-a antagonist, protected against
OHC damage and cisplatin-induced hearing loss. These studies suggest that controlling inﬂammation by inhibition of STAT1-
dependent pathways in the cochlea could serve as an effective approach to treat cisplatin ototoxicity and improve the overall
quality of life for cancer patients.
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Ototoxicity and nephrotoxicity are common side effects of
cisplatin in cancer chemotherapy. However, unlike nephro-
toxicity, which could be alleviated by diuresis and antiox-
idants, ototoxicity is more difﬁcult to treat, owing primarily to
an incomplete understanding of the mechanism(s) involved in
this process. The generation of reactive oxygen species
(ROS) is considered critical for producing cisplatin ototoxi-
city.
1 However, it is not entirely clear how ROS contribute to
cisplatin ototoxicity.
ROS serve as a principal mediator of damage to outer hair
cells (OHCs). ROS are produced primarily by the cochlear-
speciﬁcNADPHoxidaseisoform,nitro-L-argininemethylester
(NOX3),
2 which is activated and induced by cisplatin.
Scavenging of ROS by antioxidants reduces the cisplatin-
induced expression of NOX3.
3,4 ROS produced through
NOX3 induce the expression of a number of genes, including
transient receptor vanilloid-1 (TRPV1) channels in the OHCs,
activation of which promotes apoptosis. Knockdown of TRPV1
by round window application of short interfering RNA (siRNA)
reduces cisplatin-induced hearing loss in rats,
3 suggesting that
this could be an effective otoprotective strategy.
The role of inﬂammation in the development of hearing loss
was suggested from evidence that corticosteroid protected
against sensorineural hearing loss.
5 Later studies demon-
strate that the cochlea can mount an inﬂammatory response
as a result of immune challenges or toxic insults. Pro-
inﬂammatory cytokines, such as interleukin-1b (IL-1b) and
tumor necrosis factor-a (TNF-a), increase inﬂammatory
mediators in cultured spiral ligament (SL) ﬁbrocytes.
6 Induc-
tion of inﬂammation in the mouse cochlea was observed
following antigen challenge to the inner ear.
7 Recent studies
have implicated inﬂammation in cisplatin-induced cell death.
For example, cisplatin increased the expression of inﬂamma-
tory cytokines in UB/UE1 utricular epithelial cells, and in the
cristae ampullae and utricles isolated from mice.
8 Cisplatin
also mediates inﬂammation in the cochlea which was
attenuated by ﬂunarizine, an activator of NF-E2-related
factor-2 (Nrf2)/heme oxygenase-1 (HO-1).
9
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www.nature.com/cddisVarious transcription factors have been linked to cisplatin-
mediated inﬂammation in the cochlea. Inducible nitric oxide
synthase (iNOS), a mediator of inﬂammation, is induced
through nuclear factor-kB (NF-kB) and is associated with
damage to the cochlea.
10 Activation of NF-kB and activator
protein-1(AP-1)increasedcytokineexpressionandapoptosis
in the cochlea and in immortalized cochlear cells derived from
the organ of Corti.
11 Signal transducer and activator of
transcription-1 (STAT1) is also implicated in cisplatin-induced
apoptosis of mouse utricular hair cells in vitro.
12 However, it is
still unclear whether STAT1 mediates damage to OHCs in
cisplatin-induced hearing loss.
STAT1 is a cytoplasmic transcription factor involved in
signaling cascades initiated by cytokines and cellular stress.
These signals promote the phosphorylation of STATs in the
cytoplasm on tyrosine 701 (Tyr
701) and serine 727 (Ser
727).
STAT1 then translocates to the nucleus, where it regulates
genes involved in inﬂammation, such as iNOS,
13 cyclo-
oxygenase-2 (COX-2)
14 and TNF-a,
15 and genes linked to
apoptosis, such as Fas, TNF-related apoptosis-inducing
ligand (TRAIL) and caspases.
16 STAT1 also mediates cell
apoptosis by cisplatin in coordination with the cell-cycle
regulator p53.
17 In fact, in some cell types, cisplatin activation
ofSTAT1isabsolutelydependentonp53,asitisnotobserved
in p53-null cells.
18
This study tests the hypothesis that STAT1 couples
cisplatin-mediated ROS generation to inﬂammation in the
cochlea, which produces hearing loss. We show that ROS
generation through NOX3 is critical for cisplatin-induced
Ser
727 phosphorylation of STAT1 in cultured organ of Corti
hair cells (UB/OC-1) and rat cochlea. Knockdown of STAT1
inhibited cisplatin-induced inﬂammation and apoptosis, and
protected against ototoxicity. Furthermore, inhibition of TNF-a
by etanercept reduced the damage and loss of OHCs, and
attenuated cisplatin ototoxicity. These data support an
essential role of STAT1 in mediating cisplatin ototoxicity.
Results
Cisplatin increases STAT1 activity in UB/OC-1 cells and
rat cochlea. UB/OC-1 cells exposed to cisplatin (2.5mM) for
up to 120min indicated increased Ser
727-phosphorylated
STAT1 (p-STAT1). The levels of p-STAT1 peaked in 45min
and remained elevated for at least 120min (Figure 1a).
STAT1 activation was dose-dependent with cisplatin concen-
trations from 2.5 to 10mM (Supplementary Figure 1A).
Cisplatin at 2.5mM was chosen for future experiments
because this dose promotes STAT1 activation and closely
estimates the clinical plasma concentrations of cisplatin.
19
Exposure to 50mM epigallocatechin gallate (EGCG), a
STAT1 inhibitor,
20 reduced cisplatin-induced p-STAT1
(Supplementary Figure 1B). Cisplatin did not produce any
STAT1 Tyr
701 phosphorylation, assessed over a period of
8h, in contrast with increased Tyr
701 p-STAT1 induced by
interferon-gamma (IFN-g) (Supplementary Figure 1C).
Cisplatin also increased STAT1 luciferase activity, which
peaked by 8h and returned to baseline by 12h
(Supplementary Figure 1D). Cisplatin-increased STAT1
luciferase activity was attenuated by incubation with EGCG
(50mM) (Supplementary Figure 1E) or by STAT1 short
interfering RNA (siRNA) (Figure 1c). As anticipated, IFN-g
signiﬁcantly increased STAT1 luciferase activity 10.2±0.7-
fold (mean±S.E.M.) (Supplementary Figure 1F), a fold
greater than that observed with cisplatin, which averaged
4.8±0.4-fold (Supplementary Figure 1F).
Incubation of UB/OC-1 cells with 10nM STAT1 siRNA for
48h reduced the basal STAT1 protein by 70±13%
(Figure 1b) and STAT1 mRNA by B90% (Supplementary
Figure 1H), indicating effective knockdown of STAT1. STAT1
siRNA reduced basal and cisplatin-stimulated Ser
727
p-STAT1 activity without altering the levels of b-actin, used
to ensure equal loading of the proteins (Figure 1b). STAT1
siRNA also reduced the basal and IFN-g-stimulated Ser
727
p-STAT1 activity by 85±0.84% in the UB/OC-1 cells
(Supplementary Figure 1I), indicating that STAT1 is a down-
stream effector of cisplatin. Scramble siRNA does not affect
p-STAT1 activity, compared with cells not administered
siRNA, indicating that the transfection process did not
produce stress to the cells (Supplementary Figure 1G).
Cisplatin increased nuclear translocation of STAT1, as
indicated by 40,6-diamidino-2-phenylindole (DAPI, nuclear
stain) and Ser
727 p-STAT1 immunolabeling. DAPI-stained
nuclei were deep blue to purple in all the treatment groups
examined. Nuclear p-STAT1 labeling (green) was more
intense in the cisplatin-treated cells as compared with
scramble siRNA- or STAT1 siRNAþcisplatin-treated cells.
STAT1 nuclear translocation is also indicated by color
differences in the merged images, which changed from deep
blue/purple in the scramble siRNA group and the scramble
siRNAþcisplatin group to light blue/green in the scramble
siRNAþcisplatin group (Supplementary Figure 2A). STAT1
siRNA produced signiﬁcant knockdown of STAT1 in UB/OC-1
cells (Supplementary Figure 2B).
STAT1 siRNA reduced STAT1 immunolabeling in the rat
cochlea when administered by the trans-tympanic route
followed by intraperitoneal (i.p.) administration of vehicle or
cisplatin (11mg/kg) 2 days later. Low baseline p-STAT1
immunoreactivity was observed in the cochleae from rats
administered scramble siRNA alone, which were reduced by
STAT1 siRNA. Cisplatin increased p-STAT1 immunoreactiv-
ity in the cochleae, which was reduced by trans-tympanic
STAT1 siRNA (Figure 1d). Increases in p-STAT1 immunor-
eactivity were observed in the OHCs, stria vascularis (SVA),
SL and spiral ganglion (SG) cells. Trans-tympanic adminis-
trationofsiRNAtoratsreducedthep-STAT1immunoreactivityin
these regions (Figure 1d). p-STAT1 immunolabeling redistrib-
uted from the cytoplasm to the nucleus in OHCs following
administration of cisplatin (Figure 1e). Nuclear distribution of
p-STAT1intheOHCswasreducedbySTAT1siRNApretreatment
(Figure 1e). STAT1 knockdown in the cochlea is demonstrated by
immunoﬂuorescent labeling (Supplementary Figures 3A and B)
and conﬁrmed by real-time polymerase chain reaction (PCR)
determination of STAT1 mRNA (Supplementary Figure 3C).
Cisplatin-induced STAT1 activation involves ROS
generation through NOX3 NADPH oxidase. Cisplatin
ototoxicity is mediated, in part, by ROS produced through
NOX3.
2,3 ROS regulates STAT1 phosphorylation in
pancreatic cancer cells by maintaining Janus kinase-2
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Cell Death and Disease(JAK2) in a constitutively active state.
21 We show that
cisplatin-increased p-STAT1 was reduced by inhibiting
NADPH oxidase with diphenyliodonium (DPI), implicating
ROS in STAT1 activation in the cochlea. Furthermore,
hydrogen peroxide (H2O2,5 0 mM) increased p-STAT1 in
UB/OC-1 cells (Figure 2a). In addition, knockdown of NOX3
by siRNA inhibited cisplatin-induced STAT1 activation
(Figure 2b). We routinely obtained 450% knockdown of
NOX3 expression by siRNA in UB/OC-1 cultures (Figure 2c),
which resulted in reduced cisplatin-induced ROS generation
(Figure 2d). Thus, NOX3 contributes signiﬁcantly to cisplatin-
mediated ROS generation in UB/OC-1 cells. Trans-tympanic
administration of NOX3 siRNA was shown to reduce NOX3
expression in the cochlea.
4 Cochlea excised from rats
administered NOX3 siRNA trans-tympanically showed
reduced cisplatin-induced p-STAT1 levels (Supplementary
Figure 4). Overall, these data support a role of ROS
generation (through NOX3) in the activation of STAT1 in
the cochlea.
STAT1 mediates cisplatin-induced apoptosis. Treatment
of UB/OC-1 cells with cisplatin has been shown to increase
cell apoptosis.
3 To test the role of STAT1 activation in
mediating this process, cells were transfected with a
scramble or STAT1 siRNA prior to cisplatin administration.
Minimal cell death (B7%) was produced by the scramble
sequence (Figures 3a and b). Cisplatin increased UB/OC-1
cell apoptosis by B30%, which was abolished by STAT1
siRNA (Figures 3a and b), implicating STAT1 in cisplatin-
induced apoptosis. Cisplatin-induced p53, caspase-3 and
Bax proteins were abolished by STAT1 siRNA (Figures 3c
and d). Similarly, cisplatin-induced Bax and downregulation
of Bcl2 expression were abrogated by STAT1 siRNA
(Supplementary Figure 5).
STAT1 siRNA reduced cisplatin-induced hearing loss
and damage to OHCs. Rats were treated with a scramble
or STAT1 siRNA by trans-tympanic injection, followed by
cisplatin 2 days later. Auditory brainstem responses (ABRs)
Figure 1 Cisplatin activates STAT1 in UB/OC-1 cells and in the rat cochlea. (a) UB/OC-1 cells were treated with 2.5mM cisplatin for different time periods and STAT1
activation was determined by western blotting of whole-cell lysates. Activation of STAT1 (p-STAT1/STAT1) is indicated below. (b) UB/OC-1 cells were transfected with
scramble siRNA or STAT1 siRNA for 48h before cisplatin treatment for 45min. Cell lysates were prepared and used in western blot studies for Ser
727 p-STAT1. (c) UB/OC-1
cells were co-transfected with a plasmid vector encoding STAT1 luciferase, along with a scramble or STAT1 siRNA. This was followed 24h later with vehicle or cisplatin
(2.5mM) for 8h. Lysates were prepared and used for determination of luciferase activity. Co-transfection of a plasmid expressing Renilla luciferase allows normalization of
luciferase activity in each well. (d) Immunolabeling studies were performed on the cochlear sections isolated from rats treated with vehicle or cisplatin (11mg/kg, i.p.) for 72h
following trans-tympanic administration of scramble or STAT1 siRNA (0.9mg). Ser
727 p-STAT1 immunolabeling is indicated by green ﬂuorescence whereas cell nuclei are
deﬁnedby DAPI staining as indicated.Increased immunoﬂuorescence is observed in the OHC, SVA,SG cells and SL. The scale bar shown in the lower right panel measures
50mm. (e) Magniﬁed view of the OHC from panel d. The arrows indicate the three rows of OHCs. The scale bar shown in the lower right panel measures 10mm. Data are
presented as mean±S.E.M. The asterisks (*) and (**) denote statistically signiﬁcant difference from the vehicle/scramble- and the scrambleþcisplatin-treated group,
respectively (Po0.05, n¼3)
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Cell Death and Diseasewere assessed before and 3 days following cisplatin
administration. Scramble siRNA produced minimal change
in ABR thresholds from pre-treatment values. Cisplatin
elevated ABR thresholds, which averaged 25±3, 35±5
and 42±4decibels (dB), at frequencies of 8, 16 and 32kHz,
respectively. STAT1 siRNA signiﬁcantly attenuated cisplatin-
induced hearing loss (Po0.05, n¼6) (Figure 4a). Cochleae
obtained from animals treated with STAT1 siRNA alone
showed no damage in OHC morphology, but reduced
cisplatin-induced damage assessed by scanning electron
microscopy at the base of the cochlea (Figure 4b), as
indicated by arrows. A 75±6% destruction or loss of OHCs
was observed with cisplatin, which was attenuated by STAT1
siRNA (Figure 4c).
STAT1 mediates cisplatin-induced inﬂammation. STAT1
regulates a number of genes involved in inﬂammation, such
as iNOS,
13 COX-2
14 and TNF-a,
15 which are implicated in
ototoxicity.
22–24 Cisplatin (2.5mM) increased the levels of
COX-2, iNOS and TNF-a proteins in UB/OC-1 cells, which
were suppressed by STAT1 siRNA (Figures 5a–c). TNF-a
levels were 133±9%, 92±5% and 72±9% of scramble
siRNA control cells for the cisplatin, the STAT1
siRNAþcisplatin and the STAT1 siRNA group,
respectively. iNOS levels were 172±5%, 104±2% and
100±1% of scramble siRNA controls for the cisplatin, the
STAT1 siRNAþcisplatin and the STAT1 siRNA group,
respectively. In addition, COX-2 levels were 192±5%,
95±10% and 100±1% for the respective groups. Similar
changes were also observed in the expression of their genes
(Figure 5d). The respective TNF-a expressions were
2.2±0.4, 0.4±0.1 and 0.2±0.1-fold of control cells treated
with scramble siRNA. The respective iNOS expressions were
2.6±0.1, 1.1±0.1 and 1.0±0.1-fold of control cells treated
with scramble siRNA, whereas those of COX-2 expression
for these groups were 4.5±0.1, 1.8±0.1 and 1±0.1-fold.
Interestingly, STAT1 siRNA suppressed the basal levels of
TNF-a mRNA and protein, but did not affect the basal levels
of iNOS or COX-2, suggesting differences in the regulation of
these genes by STAT1. These data implicate STAT1 in
mediating cisplatin-induced inﬂammation in vitro.
To determine whether cisplatin induces inﬂammation
in vivo, we monitored the levels of TNF-a and CD14 in the
cochlea. CD14 immunolabeling serves as a marker for
immune cells inﬁltration
25 into the cochlea. Immunolabeling
of TNF-a and CD14 was observed in the SVA, SL, spiral
limbus, SG and OHCs in animals treated trans-tympanically
with scramble or STAT1 siRNA. These proteins were
colocalized, based on merged images. Cisplatin increased
the immunolabeling of these proteins at all of these sites.
Figure2 ROSareessentialforcisplatin-mediatedSTAT1phosphorylation.(a)UB/OC-1cellswerepre-treatedwithvehicleorDPI(10mM),followedbycisplatintreatment
for 45min. STAT1 activation was determined by western blotting. H2O2 (100mM) treatment served as the positive control for ROS generation. (b) Cells were transfected with
scramble or NOX3 siRNA (5nM) for 48h, the culture media was replaced with fresh media and cells were exposed to vehicle or cisplatin (2.5mM) for 45min. NOX3 siRNA
blunted the activation of STAT1 by cisplatin without altering basal STAT1 levels. (c) UB/OC-1 cells were transfected with either scramble or NOX3 siRNA (5nM) for 48h,
followed by cisplatin (2.5mM) treatment for another 24h. NOX3 mRNA, measured by real-time RT-PCR, showed a 2.7±0.2-fold increase by cisplatin, which was reduced to
0.3±0.1-fold in the NOX3 siRNAþcisplatin group. NOX3 siRNA added alone reduced NOX3 mRNA to 0.3±0.1-fold. (d) ROS generation was measured in UB/OC-1 cells
transfected with either scramble or NOX3 siRNA (5nM) for 48h, followed by treatment with cisplatin (2.5mM) for 15min. Cells were then incubated with 5mMH 2DCFDA dye
for15minandROSgeneration(greenﬂuorescence)wasvisualizedbyconfocalmicroscopy.DIC,differentialinterferencecontrast.Dataarepresentedasmean±S.E.M.The
asterisks (*) and (**) denote statistically signiﬁcant difference from the vehicle/scramble- and the scrambleþcisplatin-treated group, respectively (Po0.05, n¼4). The scale
bar shown measures 10mm
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Cell Death and DiseaseHowever, trans-tympanic STAT1 siRNA suppressed the
increases in these inﬂammatory markers (Figures 6a and b),
implicating STAT1 in the induction of TNF-a and CD14 in vivo,
and suggesting colocalization of both of these proteins in
cochlear cells. Additional studies also indicated signiﬁcant co-
regulation of both TNF-a and Ser
727 p-STAT, especially
following cisplatin administration (Supplementary Figure 6).
These data implicate STAT1 in the induction of both TNF-a
and CD14 in the cochlea by cisplatin. Similarly, we observed
an induction in the expression of TNF-a, COX-2 and iNOS
(Supplementary Figures 7A–C) by cisplatin in the cochlea,
which were reduced by STAT1 siRNA. These data implicate
STAT1 in mediating cisplatin-induced cochlear inﬂammation
in vivo.
The intensity of labeling suggests that CD14 and TNF-a could
be expressed by normal cells in the cochlea, in addition to
resident immune cells and those recruited from the circulation.
We demonstrated a similar pattern of co-labeling for CD45, a
known marker for immune cells, and TNF-a (Supplementary
Figure 8). Furthermore, increased CD14 and CD45 ﬂuorescent
labeling was observed in UB/OC-1 cells treated with cisplatin, as
assessed by ﬂow cytometry (Supplementary Figure 9). These
data may indicate that resident cells in the cochlea, such as
OHCs,canproduceimmunecellmarkers(suchasCD14,CD45)
and cytokines (such as TNF-a) upon stimulation by oxidative
stress or cytokines.
Suppression of inﬂammatory mediators reduces
cisplatin-mediated apoptosis. The signiﬁcance of iNOS,
COX-2 and TNF-a in mediating cisplatin-induced apoptosis
was evaluated by using inhibitors of these proteins in UB/OC-1
cells. Apoptosis, measured by Annexin-V–ﬂuorescein
isothiocyanate (FITC) labeling, indicated a small but
signiﬁcant increase in apoptotic cells to 11±1% produced
by incubation of cells with TNF-a (100ng/ml). TNF-a antibody
reduced TNF-a-mediated apoptosis (Figure 7a). TNF-a
increased the levels of Bax, cleaved caspase-9 and
cleaved caspase-3, which were reduced by the TNF-a
antibody (Figure 7b). Treatment of UB/OC-1 cells with
cisplatin (20mM) produced 30±2% apoptotic cell death,
which was reduced by pretreatment with the TNF-a antibody
to 7±1% (Figure 7c). These data are consistent with a role of
TNF-a in cisplatin-mediated apoptosis in vitro.
Pretreatment of UB/OC-1 cells with 1mM No-nitro-L-
arginine methyl ester hydrochloride (L-NAME, a nonselective
inhibitor of iNOS)
21 or 10mM SC791 (a COX-2 inhibitor)
reduced cisplatin-mediated apoptosis. The basal levels of
apoptosis were less than 1%, whereas cisplatin-mediated
apoptosiswas observed in38±2%of cells.Pretreatment with
L-NAME or SC791 reduced apoptosis to 17±2% and
19±2%, respectively (Figure 7d). These data are consistent
with roles of iNOS and COX-2 in mediating cisplatin
ototoxicity.
Figure 3 STAT1 siRNA reduced the cisplatin-mediated apoptosis of UB/OC-1 cells. (a) UB/OC-1 cells were transfected with scramble or STAT1 siRNA for 48h, followed
bycisplatin(20mM)foranadditional24h.ApoptosiswasdeterminedbymeasuringthepercentageofAnnexin-positiveandAnnexinpluspropidiumiodide-positivecells(lower
rightandupperright quadrantrespectively)by ﬂowcytometry.(b)Percentageof apoptoticcellsfor eachtreatmentas determined inpanela andplottedasthemean±S.E.M.
(*Po0.05,n¼3).(candd)UB/OC-1cellsweretransfectedwithscrambleorSTAT1siRNAfor48h,followedbycisplatin(20mM)foranadditional24h.(c)Cellswereusedto
determine the levels of p53, p-STAT1, STAT1 and b-actin (for normalization). (d) Cisplatin increased the levels of Bax and cleaved caspase-3, which were attenuated by
STAT1siRNA. Theﬁgureshownis representative of foursimilar experimentsshowingsimilar results.Dataare presentedas mean±S.E.M.Theasterisks(*) and(**) indicate
statistically signiﬁcant difference from the scramble siRNA group or the cisplatin-treated group, respectively (Po0.05)
STAT1 and cisplatin-induced ototoxicity
T Kaur et al
5
Cell Death and DiseaseFigure4 Cisplatin-inducedhearinglossinratsisdependentonSTAT1activation.(a)ABRthresholdswererecordedinWistarratstreatedwithcisplatin(11mg/kg,i.p.)for
72h following 48h trans-tympanic administration of scramble or STAT1 siRNA (0.9mg). (b) Scanning electron microscopic studies were performed on the cochleae. The
representativeimageshowssigniﬁcantdamagetoOHCs(whitearrows)bycisplatin,whichisabsentinthepresenceofSTAT1siRNA.(c)Quantitativeanalysisofthescanning
electron micrographs. Data are presentedas mean±S.E.M.The asterisks(*) and(**) indicate statisticallysigniﬁcant differencefrom thescramble or thescrambleþcisplatin
treatment group (Po0.05, n¼6)
Figure 5 Cisplatin increases the expression and transcription of pro-inﬂammatory mediators through the STAT1-dependent pathway. (a–c) UB/OC-1 cells were
transfected with scramble or STAT1 siRNA for 48h, followed by cisplatin (2.5mM) for 24h. Cell lysates were then used for western blotting studies to determine the levels of
TNF-a(a),iNOS(b)andCOX2(c).b-Actinlevelswereusedfornormalization.(d)mRNAlevelsofiNOS,COX2andTNF-aweredeterminedbyreal-timeRT-PCRinUB/OC-1
cultures treated as described in panels a–c. Data are presented as mean±S.E.M. The asterisks (*) and (**) denote statistically signiﬁcant difference from the scramble- and
the scrambleþcisplatin-treated group, respectively (Po0.05, n¼4)
STAT1 and cisplatin-induced ototoxicity
T Kaur et al
6
Cell Death and DiseaseInhibition of TNF-a by etanercept protects against
cisplatin-induced ototoxicity. To determine the relevance
of TNF-a to cisplatin ototoxicity in vivo, rats were administered
vehicle or etanercept (250mg/50ml per ear) by the trans-
tympanic route, followed by cisplatin (11mg/kg, i.p.). Hearing
thresholds were assessed 3 days later. Cisplatin signiﬁcantly
increased ABR thresholds, assessed at 8-, 16- and 32-kHz
frequencies (Figure 8a), which were signiﬁcantly reduced by
trans-tympanic etanercept. ABR threshold shifts were 32±4,
33±4a n d5 2 ±3dB, measured at 8, 16 and 32kHz,
respectively, following cisplatin administration. Threshold
shifts in the etanerceptþcisplatin group were 12±2, 12±2
and 15±2dB, assessed at 8, 16 and 32kHz, respectively.
Scanning electron micrograph images obtained from the
cochleae of these rats show substantial damage or loss of
OHCs (indicated by arrows) by cisplatin in the basal turn of the
cochlea, but statistically signiﬁcant protection with etanercept
(Figure 8b). The percentage of OHCs showing damage or loss
in the cochleae by cisplatin is shown in Figure 8c. Cisplatin
produced damage or loss of 58±6% of OHCs, whereas
pretreatment with etanercept signiﬁcantly reduced this to
6±3% of OHCs. These data are consistent with the
conclusion that etanercept protects against cisplatin-induced
damage or loss of OHCs and are in agreement with measures
of ABRs.
Discussion
The data presented in this paper implicate STAT1 in cisplatin-
mediated ototoxicity. STAT1 is rapidly activated by cisplatin
through ROS generation by means of NOX3 NADPH oxidase.
KnockdownofSTAT1bysiRNAreducedapoptosisinUB/OC-1
cellsanddecreasedcisplatin-mediateddamage/lossofOHCin
theratorganofCorti.DownstreameffectorsofSTAT1,suchas
TNF-a, COX2 and iNOS, also contributed to cisplatin-induced
apoptosis and ototoxicity. Furthermore, increases in these
inﬂammatory mediators were associated with increased
immune (CD14- and CD45-positive) cells in the cochlea.
Importantly, inhibition of TNF-a reduced cisplatin-induced
ototoxicity. These data suggest that STAT1 couples ROS to
inﬂammation in the cochlea and indicate that inhibition of this
molecule or its downstream targets could ameliorate cisplatin
ototoxicity.
Increased inﬂammatory markers induced by cisplatin were
widely distributed in cochlear regions such as OHCs, SG,
SVA, SL and spiral limbus. These markers showed diffused
labeling, rather than more localized and discrete labeling, as
would be anticipated from resident immune cells or the
recruitment of circulating immune cells. This observation
suggests that the resident, non-immune cells of the cochlea
could be stimulated to produce inﬂammatory markers. The
Figure 6 Cisplatinincreasesinﬂammation inratcochlea.(a)RatsweretreatedwithscrambleorSTAT1siRNAby trans-tympanicinjectionsfollowedbyvehicleorcisplatin
(11mg/kg, i.p.) 48h later. The rats were killed 72h following the administration of vehicle or cisplatin. The cochleae were excised and processed for immunohistochemistry.
Mid-modiolar sections of the cochlea were co-labeled with CD14 and TNF-a antibodies, followed by ﬂuorescein- (green) or TRITC (red)-labeled secondary antibodies.
Cisplatin increased CD14 and TNF-a immunoreactivity in cochleae treated with scramble siRNA. However, the increases in immunolabeling were attenuated in cochlea
pretreatedwithSTAT1siRNA.Themergedpanels(yellow)indicatecolocalizationofCD14andTNF-a.Thescalebars(rightlowerpanel)indicate50mm.(b)Magniﬁedviewof
the OHCs presented in panel a. The arrows indicate three rows of OHCs. The scale bar indicates 10mm
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Cell Death and Diseaseoverall increase in immunolabeling could reﬂect labeling from
resident and recruited immune cells, and resident cochlear
non-immune cells. This conclusion is supported by the
observation that UB/OC1 cells, a model of cochlear hair cells,
could be induced to express CD14 and CD45 markers.
STAT1 is an important component of signal transduction
pathways mediated through inﬂammatory cytokines. Maximal
transcriptional activation of STAT1 involves Tyr
701 and Ser
727
phosphorylation,
26 the latter involving mitogen-activated
protein kinases (MAPKs).
27 Our data indicate that ROS have
a critical role in mediating the Ser
727 phosphorylation of
STAT1 in UB/OC-1 cultures and the cochlea. STAT1 Ser
727
phosphorylation and activity were reduced by inhibition or
knockdown of NADPH oxidase, implicating ROS in this
process. ROS are generally linked to increased lipid perox-
idation, providing the rationale for using antioxidants to treat
cisplatin ototoxicity.
28 We suggest dual roles of ROS in the
cochlea, promoting both oxidative stress and inﬂammation.
Cisplatin did not increase STAT1 Tyr
701 phosphorylation in
UB/OC-1 cells, even though both sites were phosphorylated
in cells exposed to IFN-g.
Several mechanisms are believed to mediate cisplatin-
induced apoptosis. The ‘traditional’ mechanism involves
covalent binding of cisplatin to guanine bases on DNA; the
formation of inter- and intra-strand chain cross-linking; and
induction of p53, cell-cycle arrest and apoptosis.
29 ROS
generated bycisplatin could increaselipid peroxidation, which
alters enzymes and structural proteins, and direct the cell to
an apoptotic pathway. As indicated in this study, cisplatin-
induced apoptosis could involve the inﬂammatory pathway.
This latter pathway likely contributes signiﬁcantly to cisplatin
ototoxicity, based on the in vivo effectiveness of etanercept,
anantagonistofTNF-a.ItisstillunclearwhetherDNAdamage
contributes to the cisplatin-mediated activation of STAT1 in
UB/OC-1 cells and the cochlea. Interestingly, knockdown of
STAT1 by siRNA attenuated cisplatin-mediated p53 activa-
tion, suggesting that STAT1 is an essential regulator of p53
activity. The rapid activation of STAT1 by cisplatin contrasts
with the slower pace of induction of DNA-repair enzymes,
such as xeroderma pigmentosium A (XPA), by this drug.
30
Activation of STAT1 was abolished following knockdown of
NOX3 by siRNA, suggesting that ROS generation is the
primary mediator of STAT1 activation
4 in UB/OC-1 cells and
the cochlea. Activation of STAT1 was observed following
activation of TRPV1 in the cochlea. This mode of STAT1
activation was dependent on ROS but was independent of
p53 activation.
4
We showed that cisplatin increases the expression of
COX-2, iNOS and TNF-a, downstream targets of STAT1,
which likely contributed to inﬂammation and apoptosis in the
cochlea. Inhibition of COX-2, iNOS or TNF-a led to reduced
cisplatin-mediated apoptosis of UB/OC-1 cells, whereas
Figure7 Roleofinﬂammatorypathwaysinmediatingcisplatin-inducedhearingloss.(a)UB/OC-1cellswerepre-treatedwithpre-immuneserumoramonoclonalantibody
against TNF-a,f o l l o w e db ya d d i t i o no fT N F - a. The cells were harvested 24h later and percent apoptosis was determined by Annexin-V–FITC staining by ﬂow cytometry. TNF-a
producedasigniﬁcantincrease(Po0.05,n¼4)inapoptosis,whichwasabrogatedbythemonoclonalantibodyagainstTNF-a.(b)Lysatespreparedfromcellstreatedasinpanel
ashowedincreasedlevelsofBax,cleavedcaspase-9andcleavedcaspase-3bywesternblotting.Blotswerenormalizedtob-actin.(c)UB/OC-1cellswerepretreatedwithvehicle
(control),pre-immuneserumorTNF-aantibody,followedbyadministration of vehicleorcisplatin (20mM).Cisplatinincreasedthepercentageofapoptoticcellsinthesegroupsby
24h, which was signiﬁcantly reduced by the TNF-a monoclonal antibody (Po0.05, n¼4). (d) Treatment of UB/OC-1 cells with L-NAME or SC-791, inhibitor of iNOS or COX-2,
respectively, resulted in partial inhibition of cisplatin-induced apoptosis (Po0.05, n¼4). Data are presented as mean±S.E.M. The asterisks (*) and (**) indicate statistically
signiﬁcant difference from vehicle and cisplatin-treated cells, respectively
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Cell Death and Diseaseinhibition of TNF-a (by etanercept) reduced cisplatin-induced
hearing loss. These data suggest that targeting STAT1-
dependent inﬂammation is a useful approach for treating
cisplatin ototoxicity. The effectiveness of etanercept against
cisplatin ototoxicity would suggest that TNF-a is a key
inﬂammatory mediator of OHC damage/death and ototoxicity.
TNF-a also has a signiﬁcant role in cisplatin-induced
nephrotoxicity. Inhibition of TNF-a-converting enzyme
(TACE), the enzyme, which cleaves and releases TNF-a into
the circulation, reduced cisplatin-mediated kidney injury,
thereby implicating TNF-a in this process.
31
In previous studies, we have successfully used round
window or trans-tympanic delivery of siRNAs to the cochlea to
effect otoprotection.
3,4,32 While these siRNAs produced
efﬁcient knockdown of their target proteins, it is yet unclear
how they enter the cells of the cochlea. Administration of
siRNAs through the intravenous route produced a signiﬁcant
accumulation of the intact siRNA in the proximal tubules of the
kidneys.
33 This selective accumulation of siRNAs was
presumably due to their uptake through the oligonucleotide
transporter localized speciﬁcally to the proximal tubules. As
the kidneys and cochlea share a number of similarities,
28 the
cochleacouldalsoexpresstheseoligonucleotidetransporters
to effect efﬁcient knockdown of different genes linked to
ototoxicity.
Targeting inﬂammation by using corticosteroids or etaner-
cept has been an effective strategy in treating immune-
mediated inner ear disease (IMIED). Etanercept reduces
hearing loss associated with experimentally induced labyr-
inthitis in guinea pigs sensitized to keyhole limpet hemo-
cyanin
34 and inﬂammation in the endolymphatic sac,
7 two
animal models of IMIED. The beneﬁts of etanercept were
comparable to corticosteroids against experimentally induced
labyrinthitis.
35 Patients with autoimmune-induced hearing
loss respond positively to anti-inﬂammatory agents such as
glucocorticoids.
36 In addition, patients with immune-mediated
cochleovestibular disorders showed signiﬁcant improvement
when administered etanercept.
37
In summary, our data demonstrate the utility of targeting
cochlear STAT1 or STAT1-regulated genes by the trans-
tympanic route for treating cisplatin ototoxicity. Localized
delivery of drugs to the cochlea could be performed on an
outpatient basis and would limit the widespread immune
suppression and potential drug–drug interactions character-
ized by systemic administration of these agents. The ease
of trans-tympanic drug delivery suggests that this could
Figure 8 Inhibition of TNF-a by etanercept suppresses cisplatin-induced hearing loss. (a) Rats were administered vehicle or etanercept by trans-tympanic injections,
followed by vehicle or cisplatin 30min later. ABR thresholds were recorded in these groups of rats before and after 72h of cisplatin administration (11mg/kg, i.p.). Etanercept
signiﬁcantly reduced cisplatin-induced increase in ABR thresholds (Po0.05, n¼5). (b) Scanning electron microscopic studies were performed in cochleaeisolated from rats
treated as above. The representative image shows damage to OHCs (white arrows) by cisplatin, which is prevented by etanercept. (c) Quantitative analysis of the scanning
electron micrographs images. Data are presented as mean±S.E.M. The asterisks (*) and (**) indicate statistically signiﬁcant difference from the vehicle or the cisplatin
treatment group, respectively (Po0.05, n¼5)
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Cell Death and Diseaserepresent a useful route of administration of anti-inﬂammatory
agents to treat hearing loss.
Materials and Methods
Drugs and reagents. Cisplatin, EGCG, L-NAME, DPI and TRI reagent were
purchased from Sigma-Aldrich (St. Louis, MO, USA), whereas the 20,70-
dichlorodihydroﬂuorescein diacetate (H2DCFDA) dye was from EMD Biosciences
(Gibbstown, NJ, USA). SC-791 (COX-2 inhibitor) was purchased from Calbiochem
(La Jolla, CA, USA). Etanercept (Enbrel) was purchased from Amgen Wyeth
(ThousandOaks,CA,USA).Thevariousantibodiesusedandtheirdilutionswereas
follows:STAT1(1:5000), iNOS(1:1000), COX-2(1:1000),TNF-a(1:500),CD45
(1:100; from Abcam, Cambridge, MA, USA), CD14 (1:100; from Santa Cruz
Biotechnology, SantaCruz,CA,USA), p-STAT1(1:1000)(both Ser
727 and Tyr
701),
caspase-3 (1:1000), caspase-9 (1:1000) and Bax (1:1000) (Cell Signaling
Technology Inc., Danvers, MA, USA); goat anti-rabbit, donkey anti-goat and goat
anti-mouse secondary antibodies (Santa Cruz Biotechnology); and ﬂuorescent
tagged (Dylight-488 and TRITC) secondary antibodies (Jackson Immuno
Laboratories, West Grove, PA, USA).
Animal procedures and sample collection. Male Wistar rats (200–
250g) were used for this study. Pretreatment ABRs were performed immediately
before trans-tympanic application of either siRNA against STAT1 or a scramble
sequence,whichservedasacontrolfor48h.Cisplatin(11mg/kg)wasadministered
intraperitoneally 48h after siRNA administration. Another group of animals were
treated with etanercept or vehicle trans-tympanically 30min prior to the cisplatin
administration. There was no evidence of middle ear effusion or infection in these
animals. Post-treatment ABRs were then performed 72h following cisplatin
administration. Cochleae were dissected and used for total RNA, perfused with
2.5% glutaraldehyde for S.E.M. or with 4% paraformaldehyde for immuno-
histochemistry. All animal procedures used were approved by the SIU Laboratory
Animal Care and Use Committee.
Trans-tympanic administration of siRNA. The procedure performed is
similar to that used previously in our laboratory in rats.
4 A 50-ml volume of solution
was injected into the middle ear (siRNA was re-suspended in 50ml of sterile water
for the desired concentration). The rat was then left undisturbed for 15min with the
treated ear facing up. This procedure was then repeated for the other ear.
Evokedpotentials. ABRs weredeterminedas describedpreviously.
3 Animals
were tested with a stimulus intensity series that was initiated at 10dB SPL and
reached a maximum at 90dB SPL, with 10-dB increments. The auditory stimuli
included tone bursts at 8, 16 and 32kHz, with a 5-ms plateau and a 1-ms rise/fall
time presented at a rate of 5/s. Threshold was deﬁned as the lowest intensity
capable of evoking a reproducible, visually detectable response, with two distinct
waveforms and minimum amplitude of 0.5mV.
Morphological studies by scanning electron microscopy. Imme-
diately after completion of post-treatment ABRs, deeply sedated rats were
euthanized, their cochleae were harvested and were processed as described
previously.
3 Sputter-coated cochleae were then viewed and photographed with a
Hitachi S-500 scanning electron microscope (Hitachi Ltd, Tokyo, Japan).
Hair cell count. Hair cell counts were performed as described previously.
3 Two
representative areas of the basal turn, middle turn, and apex and hook portion were
photographed. In each area, OHCs were counted in an area that was 10 pillar cell
heads in length. The results are presented as the percent hair cell damage per
cochlear turn. At least three cochleae from different animals per treatment group
were used.
Processing of cochleae for immunohistochemistry. Cochleae were
perfused with 4% paraformaldehyde, decalciﬁed for 4–6h by rapid decalciﬁcation
(RapidCal Immuno, BBC Biochemical, Detroit, MI, USA), parafﬁn-embedded and
sectioned. Immunolabeling studies were performed as described previously.
3,4
Slides were then imaged using a Leica confocal microscope (Buffalo Grove,
IL, USA).
Immunocytochemistry. To detect nuclear translocation of p-STAT1 after
cisplatintreatment by immunoﬂuorescence staining, UB/OC-1cells were ﬁrst plated
in a 12-well plate. After the cells adhered to the plate surface, they were transfected
with either scramble siRNA (5nM) or STAT1 siRNA (10nM) by using the RNAfectin
transfection reagent for 48h. At the end of 48h the cells were treated with cisplatin
(2.5mM) for another 45min. After the treatment, the cells were ﬁxed with 4%
paraformaldehyde(Sigma),followedbywashingwith1 PBS(phosphate-buffered
saline).Coverslipswerethenincubatedwithsolution-A–5%donkeyserum(Jackson
Immuno Laboratories) and 0.5% Triton-X (Sigma) in PBS for 30min at room
temperature. Primary antibody against p-STAT1 (1:300 dilution) in solution-A was
then added and incubated for 2h at 371C. After three washes with 1 PBS, the
cells were incubated with a Dylight-488-labeled anti-rabbit secondary antibody
(1:600 dilution) in the dark for 1h. After three washes with 1 PBS and two
washes with fresh distilled water the coverslips were mounted on glass slides by
using the Vectashield mounting medium containing DAPI (Vector Laboratories Inc.,
Burlingame, CA, USA) for nuclear staining, before examination under an Olympus
ﬂuorescence microscope.
siRNA sequences. The rodent set of siRNAs was designed based on the
homologous sequences in the rat and mouse cDNA sequences. A custom siRNA
was purchased from Qiagen (Valencia, CA, USA). Scramble siRNA was also
procured from the Human/Mouse starter kit (Qiagen). Rodent NOX3 siRNA: Target
sequence: 50-AAGGTGGTGAGTCACCCATCT-30.
3 Rodent STAT1 siRNA: Target
sequence: 50-AAGGAAAAGCAAGCGTAATCT-30.
32
siRNA transfection. DNAfectin and RNAfectin (Applied Biological Materials
Inc., Richmond, BC, Canada) were used for transfections of plasmids and siRNAs,
respectively, according to the manufacturer’s instructions. Brieﬂy, UB/OC-1 cells
were transfected with 10nM STAT1 and 5nM NOX3 siRNA or scramble siRNA in
serum-free medium for 5–8h. The culture medium was then replaced with fresh
medium for 48h. Cells were then treated accordingly.
RNA isolation and real-time RT-PCR. RNA was isolated from UB/OC-1
cell cultures as well as the rat cochleae by adding 1ml of TRI reagent to 100mg of
each cochlea or 0.5ml of TRI reagent per well of each six-well plate, and real-time
RT-PCRstudies were also performed as describedpreviously.
3,4 The cycle number
at which the sample reached the threshold ﬂuorescent intensity was termed the
cyclethreshold(Ct).TherelativechangeinmRNAlevelsbetweenuntreatedandthe
treated sample was measured using the following formula, 2
DDCt.
38 Negative
controls for both target gene and glyceraldehyde-3 phosphate dehydrogenase
(GAPDH) were used for all reaction groups. Gene-speciﬁc primer pairs were used
for thevarious reactionsand mRNAexpressionlevels werenormalizedto thelevels
of GAPDH. The primer sets were purchased from Sigma Genosys (St. Louis, MO,
USA) and were as follows:
Rodent-Bax (sense): 50-ATGGCTGGGGAGACACCTGA-30; (antisense): 50-GC
AAAGTAGAAGAGGGCAACC-30;
Rodent-Bcl2 (sense): 50-CCTTCTTTGAGTTCGGTG-30; (antisense): 50-GAGAC
AGCCAGGAGAAAT-30
Rodent-iNOS (sense): 50-CATTCTACTACTACCAGATC-30; (antisense): 50-ATG
TGCTTGTCACCACCAG-30
Rodent-COX2 (sense): 50-TGATCGAAGACTACGTGCAAC-30; (antisense): 50-GT
ACTCCTGGTCTTCAATGTT-30
Rodent-GAPDH (sense): 50-ATGGTGAAGGTCGGTGTGAAC-30; (antisense):
50-TGTAGTTGAGGTCAATGAAGG-30
Rodent-NOX3 (sense): 50-GTGAACAAGGGAAGGCTCAT-30; (antisense): 50-GA
CCCACAGAAGAACACGC-30
Rodent-STAT1 (sense): 50-CATGGAAATCAGACAGTACCT-30; (antisense): 50-TC
TGTACGGGATCTTCTTGGA-30
Rodent-TNF-a (sense): 50-CAGACCCTCACACTCAGATCA-30; (antisense): 50-TG
AAGAGAACCTGGGAGTAGA-30
Cell culture. Immortalized organ of Corti cells derived from the mouse, UB/OC-1
cells, were obtained from Dr. Matthew Holley (Institute of Molecular Physiology,
Addison Building, Western Bank, Shefﬁeld, UK) and cultured in RPMI-1640
supplemented with 10% Fetalclone-II serum (Hyclone laboratories, Inc., Logan, UT,
USA), penicillin–streptomycin and normocin (Invitrogen, Carlsbad, CA, USA). The
cultures were grown at 331C in an incubator with 10% CO2.
H2DCFDA assay. ROS generation was measured with the green-ﬂuorescent
dye H2DCFDA as described previously.
3 Brieﬂy, UB/OC-1 cells were transfected
with siRNAs (for 48h). The cells were then treated with cisplatin for 15min followed
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green ﬂuorescence by confocal microscopy.
Apoptosis detection by ﬂow cytometry. Apoptotic cells were labeled
and visualized by using the FITC–Annexin-V Apoptosis detection kit (BD
Pharmingen, San Diego, CA, USA). Brieﬂy, UB/OC-1 cells were transfected with
either scramble or STAT1 siRNA for 48h followed by treatment with cisplatin
(20mM) for another 24h. At the end of the treatment, the cells were washed with
PBS and harvested in a 0.5% trypsin/EDTA solution at 371C, centrifuged at
220 g for 5min and then immediately re-suspended in the buffer provided in the
kit. The cells (1 10
5cells/500ml) were then maintained in the dark for 15min at
room temperature with 5ml of both FITC-conjugated Alexa-V and propidium iodide,
and samples were analyzed immediately by ﬂow cytometry (FACS Calibur; Becton
Dickinson, San Jose, CA, USA). Results were analyzed by using the CellQuest
software provided with the FACS machine. Early apoptotic cells are shown in the
lower right-hand quadrant of each dot plot, whereas necrotic or late apoptotic cells
are shown in the upper right-hand quadrant of the plot.
Flow cytometry for CD14 and CD45 expression. UB/OC-1 cell were
treated with either vehicle, cisplatin (2.5mM/ml) or IFN-g (250U/ml) for 24h. At the
end of the 24-h incubation period, the cells were resuspended in a 1 PBSþ10%
fetal calf serumþ1% sodium azide solution followed by staining with the
unconjugated primary antibody solution (CD45 and CD14 1:100 in 3% BSA in
1 PBS) at 41C for 30min. After washing the pellet with 1 PBS, the cells were
stained with the secondary antibody solution (Dylight-488 goat anti-rabbit; 1:200 in
3% BSA in 1 PBS) for 30min in the dark at 41C. Finally the pellet was
resuspended in a 1 PBAþ3% BSAþ1% sodium azide solution and labeled
cells were analyzed by ﬂow cytometry (FACS Calibur; Becton Dickinson). The
results were analyzed by using the CellQuest software provided with the FACS
machine.
Plasmid and siRNA co-transfection. UB/OC-1 cells were simultaneously
transfected with plasmid DNA (STAT1 p84/91; purchased from Panomics Inc.,
Fremont, CA, USA) and pGL3 Renilla, a gift from Dr. YY Mo (SIU School of
Medicine),byusingDNAfectinandsiRNA(STAT1orscramble)byusingRNAifectin.
Brieﬂy, for each well of a 24-well plate: (1) Plasmid DNA mix: In 32ml of serum-free
media, 0.8mg of STAT1 luciferase plasmid and 0.1mg of pGL3 Renilla luciferase
plasmid were diluted. A 2-ml volume of DNAfectin was diluted in 32ml of serum-free
media.TheDNAfectinmix was thenaddedto theplasmidmixandgentlymixedand
incubated for 20min (about 60ml total for each well). (2) siRNA mix: In 32mlo f
serum-free media, either STAT1 siRNA (10nM) or scramble siRNA (5nM) was
mixed. A 2-ml volume of RNAfectin was diluted in 32ml of serum-free media.
RNAfectin mix was added to the siRNA tube and gently mixed. This mixture was
thenincubatedfor20min(about60mltotalforeachwell).Attheendof20min,60ml
oftheplasmidmixand60mlofsiRNAmixwereaddedtoeachwellcontaining130ml
of serum-free media. The plate was then incubated at 331C for 8h, after which
serum-free media was replaced with whole media for another 36h.
Luciferase assay. UB/OC-1 cells transfected with plasmid and siRNA were
used for this experiment. Pre-treatment with EGCG was performed for half an hour
followed by treatment with cisplatin (2.5mM) for another 8h. Luciferase activity was
assessed by using the Dual-Luciferase Reporter Assay kit (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. Brieﬂy, the cells were harvested by
usingthelysisbufferprovidedinthekit.A25-ml volumeofthelysatewasmixedwith
25ml of luciferase assay substrate and luciferase activity was measured by using a
Berthold Detection Systems luminometer (Huntsville, AL, USA). To measure the
activity of the control Renilla luciferase, 25ml of stop and glo substrate was then
added to the lysate mix and luminescence was measured again. Renilla luciferase
was used for normalization.
Western blot analysis. UB/OC-1 cells were homogenized in ice-cold 50mM
Tris HCl, 10mM MgCl2 and 1mM EDTA in the presence of a protease inhibitor
mixture (Sigma) and phosphatase inhibitor-1 (Sigma). The whole-cell lysates were
then used for western blotting as described previously.
39 After transferring to
nitrocellulose membranes, the blots were probed with different primary antibodies,
followedbyahorseradishperoxidase-taggedsecondaryantibody,andvisualizedby
chemiluminescence detection (Pierce Biotechnology, Rockford, IL, USA) using
charged-coupled device LAS 4000 (Fujiﬁlm North America Corporation, Valhalla,
NY, USA). Densitometric analysis of blots was performed by using the MultiGauge
version 2.0 software.
Statistical analysis. Data are presented as mean±S.E.M. Statistical
signiﬁcance of differences among groups were performed by either Student’s
t-test or analysis of variance followed by Tukey’s post hoc test wherever
appropriate.
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